SEC Filing Summary

Neil Garry Arthur, the Chief Executive Officer and a director of Avalo Therapeutics, Inc. (AVTX), reported transactions on March 28, 2026. He acquired 64,866 Restricted Stock Units (RSUs) with a conversion price of $0.00, which were immediately converted into 64,866 shares of Common Stock. Concurrently, he disposed of 21,892 shares of Common Stock at a price of $13.89 per share. Following these transactions, Mr. Arthur holds 90,114 shares of Common Stock directly. The RSUs were granted on August 13, 2024, with vesting scheduled in three tranches on March 28, 2025, 2026, and 2027. This filing is Form 4, indicating a change in beneficial ownership.